[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES512842A0 - "procedimiento de preparar derivados carboxamidicos". - Google Patents

"procedimiento de preparar derivados carboxamidicos".

Info

Publication number
ES512842A0
ES512842A0 ES512842A ES512842A ES512842A0 ES 512842 A0 ES512842 A0 ES 512842A0 ES 512842 A ES512842 A ES 512842A ES 512842 A ES512842 A ES 512842A ES 512842 A0 ES512842 A0 ES 512842A0
Authority
ES
Spain
Prior art keywords
atom
alkyl group
lower alkyl
group
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES512842A
Other languages
English (en)
Other versions
ES8303293A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre SA
Original Assignee
Pierre Fabre SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9259785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES512842(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre SA filed Critical Pierre Fabre SA
Publication of ES8303293A1 publication Critical patent/ES8303293A1/es
Publication of ES512842A0 publication Critical patent/ES512842A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ES512842A 1981-06-23 1982-06-04 "procedimiento de preparar derivados carboxamidicos". Granted ES512842A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8112312A FR2508035A1 (fr) 1981-06-23 1981-06-23 Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central

Publications (2)

Publication Number Publication Date
ES8303293A1 ES8303293A1 (es) 1983-03-01
ES512842A0 true ES512842A0 (es) 1983-03-01

Family

ID=9259785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES512842A Granted ES512842A0 (es) 1981-06-23 1982-06-04 "procedimiento de preparar derivados carboxamidicos".

Country Status (11)

Country Link
US (1) US4478836A (es)
EP (1) EP0068999B1 (es)
JP (1) JPS584752A (es)
AT (1) ATE13422T1 (es)
AU (1) AU550774B2 (es)
CA (1) CA1202639A (es)
DE (1) DE3263734D1 (es)
ES (1) ES512842A0 (es)
FR (1) FR2508035A1 (es)
LU (1) LU90410I2 (es)
ZA (1) ZA824453B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
US5621142A (en) * 1994-02-22 1997-04-15 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
EP1434763B1 (en) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonists
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
US7038085B2 (en) * 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
ES2310715T3 (es) * 2003-02-14 2009-01-16 Pierre Fabre Medicament Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
AR045368A1 (es) * 2003-08-15 2005-10-26 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3
NZ544935A (en) 2003-08-15 2009-08-28 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
CN101175740A (zh) * 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
BRPI0610037A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de dihidrobenzofurano e uso dos mesmos
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
WO2006132307A1 (ja) 2005-06-10 2006-12-14 Pierre Fabre Medicament S.A. 安定化されたミルナシプラン製剤
WO2007008758A2 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
AU2006270039B2 (en) 2005-07-19 2013-07-04 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1980271A4 (en) * 2006-01-27 2012-04-25 Asahi Kasei Pharma Corp MEDICINE FOR TRANSNASAL ADMINISTRATION
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
EP2114868A2 (en) * 2007-02-28 2009-11-11 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010036773A1 (en) * 2008-09-24 2010-04-01 Concert Pharmaceuticals, Inc. Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
FR2941454B1 (fr) 2009-01-29 2011-04-01 Pf Medicament Proced de synthese du (1s,2r)-milnacipran
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
US20100286260A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Ltd. Milnacipran formulations
WO2011016057A2 (en) 2009-08-05 2011-02-10 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2011092065A1 (en) 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
US8916194B2 (en) 2010-08-30 2014-12-23 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
EP2699539B1 (en) 2011-04-21 2019-03-06 Emory University Cyclopropyl derivatives and methods of use
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
WO2014203277A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
IN2013MU03122A (es) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
AU2018333051B2 (en) 2017-09-15 2024-03-21 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
AU2020316013A1 (en) 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA570688A (en) * 1959-02-17 E. Speeter Merrill Antispasmodic substituted amines
CA619080A (en) * 1961-04-25 The Upjohn Company N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES
GB1415541A (en) 1972-11-30 1975-11-26 Hexachimie 1-amino-methyl-2,2-diarylcyclopropanecarboxamide

Also Published As

Publication number Publication date
JPS6323186B2 (es) 1988-05-16
ZA824453B (en) 1983-04-27
ES8303293A1 (es) 1983-03-01
CA1202639A (fr) 1986-04-01
FR2508035B1 (es) 1984-06-29
EP0068999B1 (fr) 1985-05-22
DE3263734D1 (en) 1985-06-27
JPS584752A (ja) 1983-01-11
AU8508682A (en) 1983-01-06
AU550774B2 (en) 1986-04-10
LU90410I2 (fr) 1999-08-31
EP0068999A1 (fr) 1983-01-05
FR2508035A1 (fr) 1982-12-24
US4478836A (en) 1984-10-23
ATE13422T1 (de) 1985-06-15

Similar Documents

Publication Publication Date Title
ES512842A0 (es) "procedimiento de preparar derivados carboxamidicos".
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
ATE28565T1 (de) Spiro(4.(3+n))-2-aza-alkan-3-carbonsaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
DE3762618D1 (de) Amidderivate.
SE8502017L (sv) 1,4-dihydro-4-oxonaftyridinderivat och salter derav, forfarande for framstellning av dessa jemte antibakteriella medel innefattande dessa
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
SE8102220L (sv) Anvendning av substituerade derivat av 4-fenyl-4-oxo-2-butensyra sasom lekemedel
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
ES546366A0 (es) Procedimiento para preparar derivados de 1,6-naftiridina
DK469285D0 (da) Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne
ES2135383T3 (es) Pirido(3,4-b)pirrolo(1,2-e)(1,4,5)oxadiazepinas y compuestos analogos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
SE8500451L (sv) N-substituerade aminopropansulfonsyraderivat
ES550817A0 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas
ES8307798A1 (es) Un procedimiento para la preparacion de derivados de piperazilmetil-4-dibenzofuranona, o, dibenzofuranol.
DE3370326D1 (en) Substituted 1-((3-(amino)-propoxy)-phenyl)-1-(phenyl)-propan-1-ols, their acid addition salts and quaternary salts, process for their preparation and medicines containing these compounds
IT1210914B (it) Eterociclilfenilsolfonil e fosfonilamidine sostituite, procedimento per la loro preparazione e loro uso farmaceutico.

Legal Events

Date Code Title Description
PC1A Transfer granted